eli lilly tirzepatide releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly (LLY) Gets Nod

This article analyzes the complete clinical dataset: Phase 2 results from 2023, TRIUMPH-4 Phase 3 data from December 2025, TRIUMPH-1 Phase 3 data from May 2026, TRANSCEND-T2D-1 data from June 2026, sleep apnea substudy results, safety profiles, and what the remaining TRIUMPH trials might reveal

By using this website, you acknowledge and agree that any medical services are provided by licensed healthcare providers exercising independent medical judgment and that treatment recommendations and prescriptions are subject to provider evaluation and approval

Comparando el efecto de GIP y GLP-1 con respecto a la dependencia de glucosa para el aumento de la secrecin de insulina, se observ que en islotes aislados de animales GIP es menos sensible a niveles de glucosa inferiores a 11,1 mmol/l, mientras que a mayores niveles de glucosa las dos incretinas son similares

They are both approved to help people with type 2 diabetes

Smeal, Cole M